Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study.

Peter Savas Louisa L Lo Stephen J Luen Elizabeth F Blackley Jason Callahan Kate Moodie Courtney T van Geelen Yi-An Ko Chen-Fang Weng Lironne Wein Maria João Silva Andjelija Zivanovic Bujak Miriam M Yeung Sarah Ftouni Rodney John Hicks Prudence A Francis Chee Khoon Lee Sarah-Jane Dawson Sherene Loi

Published in: Cancer discovery (2022)

Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting. This article is highlighted in the In This Issue feature, p. 2007.

Keyphrases

phase ii study
open label
combination therapy
estrogen receptor
locally advanced
machine learning
clinical trial
high throughput
squamous cell carcinoma
breast cancer cells
breast cancer risk
study protocol
radiation therapy
endoplasmic reticulum
young adults